Literature DB >> 11149527

The utility of ultrasonographically guided large-core needle biopsy: results from 500 consecutive breast biopsies.

D N Smith1, M L Rosenfield Darling, J E Meyer, C M Denison, D I Rose, S Lester, A Richardson, C M Kaelin, E Rhei, R L Christian.   

Abstract

Five hundred ultrasonographically guided large-core needle breast biopsies of solid masses were performed in 446 women. Histopathologic results were correlated with imaging findings. Ultrasonographically guided large-core needle biopsy resulted in diagnosis of malignancy (n = 124) or severe atypical ductal hyperplasia (n = 4) in 128 lesions (26%). In the remaining 372 lesions (74%), ultrasonographically guided large-core needle biopsy yielded benign pathologic results. Follow-up of more than 1 year (n = 225), results of surgical excision (n = 50), or both were obtainable in 275 (74%) of the benign lesions. No malignancies were discovered at surgical excision or during follow-up of this group of benign lesions. There were no complications related to large-core needle biopsy that required additional treatment. Ultrasonographically guided large-core needle biopsy is a safe and accurate method for evaluating breast lesions that require tissue sampling.

Entities:  

Mesh:

Year:  2001        PMID: 11149527     DOI: 10.7863/jum.2001.20.1.43

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  24 in total

Review 1.  Stereotactic and ultrasound-guided breast biopsy.

Authors:  T H Helbich; W Matzek; M H Fuchsjäger
Journal:  Eur Radiol       Date:  2003-11-13       Impact factor: 5.315

2.  [Percutaneous large core breast biopsy].

Authors:  K Prechtel; J de Waal; A Nerlich; D Hölzel; J Weitz
Journal:  Pathologe       Date:  2006-05       Impact factor: 1.011

Review 3.  Accuracy of ultrasound-guided, large-core needle breast biopsy.

Authors:  G Schueller; C Schueller-Weidekamm; T H Helbich
Journal:  Eur Radiol       Date:  2008-04-15       Impact factor: 5.315

Review 4.  Comparison of the accuracy of US-guided biopsy of breast masses performed with 14-gauge, 16-gauge and 18-gauge automated cutting needle biopsy devices, and review of the literature.

Authors:  Monica L Huang; Kenneth Hess; Rosalind P Candelaria; Mohammad Eghtedari; Beatriz E Adrada; Nour Sneige; Bruno D Fornage
Journal:  Eur Radiol       Date:  2016-11-14       Impact factor: 5.315

5.  Comparison of the underestimation rate in cases with ductal carcinoma in situ at ultrasound-guided core biopsy: 14-gauge automated core-needle biopsy vs 8- or 11-gauge vacuum-assisted biopsy.

Authors:  Y J Suh; M J Kim; E-K Kim; H J Moon; J Y Kwak; H R Koo; J H Yoon
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

6.  Vacuum-assisted stereotactic breast biopsy in the diagnosis and management of suspicious microcalcifications.

Authors:  Gül Esen; Burçin Tutar; Cihan Uras; Zerrin Calay; Ümit İnce; Onur Tutar
Journal:  Diagn Interv Radiol       Date:  2016 Jul-Aug       Impact factor: 2.630

7.  Can concurrent core biopsy and fine needle aspiration biopsy improve the false negative rate of sonographically detectable breast lesions?

Authors:  Yao-Lung Kuo; Tsai-Wang Chang
Journal:  BMC Cancer       Date:  2010-07-16       Impact factor: 4.430

8.  Intraoperative ultrasonographically guided excisional biopsy or vacuum-assisted core needle biopsy for nonpalpable breast lesions.

Authors:  Shin-Cheh Chen; Horng-Ren Yang; Tsann-Long Hwang; Miin-Fu Chen; Yun-Chung Cheung; Swei Hsueh
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

9.  Analysis of false-negative results after US-guided 14-gauge core needle breast biopsy.

Authors:  Ji Hyun Youk; Eun-Kyung Kim; Min Jung Kim; Jin Young Kwak; Eun Ju Son
Journal:  Eur Radiol       Date:  2009-10-28       Impact factor: 5.315

10.  The accuracy of frozen section analysis in ultrasound- guided core needle biopsy of breast lesions.

Authors:  Andreas H Brunner; Thomas Sagmeister; Jolanta Kremer; Paul Riss; Hermann Brustmann
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.